PHAT Phathom Pharmaceuticals, Inc.
Healthcare$11.10-2.03%ClosedMarket Cap: $885.3M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
-2.76
P/S
4.41
EV/EBITDA
-7.55
DCF Value
$-6.79
FCF Yield
-10.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
84.9%
Operating Margin
-47.1%
Net Margin
-76.8%
ROE
39.2%
ROA
-51.6%
ROIC
-53.4%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $58.3M | 79.4% | $-15.5M | $-30.4M | $— | — |
| Q4 null | $57.6M | 86.7% | $-5.9M | $-21.1M | $— | — |
| FY null | $175.1M | 87.1% | $-160.0M | $-221.2M | $— | — |
| Q3 null | $49.5M | 87.5% | $-15.3M | $-30.0M | $— | — |
| Q2 null | $39.5M | 87.2% | $-59.9M | $-75.8M | $— | — |
| Q1 null | $28.5M | 86.9% | $-78.9M | $-94.3M | $— | — |
| Q4 null | $29.7M | 87.1% | $-59.4M | $-74.5M | $— | — |
| FY null | $55.3M | 85.6% | $-277.5M | $-334.3M | $— | — |
| Q3 null | $16.4M | 85.6% | $-70.8M | $-85.6M | $— | — |
| Q2 null | $7.3M | 81.2% | $-77.3M | $-91.4M | $— | — |
| Q1 null | $1.9M | 77.7% | $-70.0M | $-82.9M | $— | — |
| Q4 2023 | $682.0K | 48.4% | $-69.9M | $-79.6M | $-1.39 | — |